Post-transplant lymphoproliferative disorders (PTLDs) are characterized by hyperproliferation of B cells due to solid organ or allogeneic hematopoietic stem cell transplant. Based on histological findings, it is divided into 4 categories. Most PTLD patients are Epstein-Barr virus (EBV) positive. Additionally, aggressive immunosuppressive therapies can also lead to PTLD. Reducing immunosuppressive regimes, antivirals, monoclonal antibodies, chemotherapy, and radiotherapy are available therapeutic options, depending on the nature and phase of the disease. This review briefly highlights pathogenesis, risk factors, prevention, and therapeutic strategies regarding PTLDs.
Keyphrases
- epstein barr virus
- hematopoietic stem cell
- diffuse large b cell lymphoma
- risk factors
- end stage renal disease
- newly diagnosed
- locally advanced
- ejection fraction
- stem cell transplantation
- chronic kidney disease
- early stage
- bone marrow
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- radiation induced
- low dose
- rectal cancer